论文部分内容阅读
目的:探讨睾酮5-α还原酶Ⅱ(SRD5A2)基因V89L多态性与影响前列腺癌预后因素的关系。方法:对V89L多态性位点用Rsa-1限制性内切酶进行酶切鉴定,观察112例前列腺癌患者和89例BPH患者的V89L(VV、VL、LL)多态性分布情况的差异及其多态性与前列腺癌患者年龄、前列腺特异性抗原(PSA)、游离PSA/总PSA值(tPSA/fPSA,F/T)、Gleason评分、临床分期的关系。结果:前列腺癌组112例与BPH组89例的V89L基因频度风险无显著性差异(χ2=3.606,df=2,P=0.165)。前列腺癌组VV和VL+LL基因型与fPSA、tPSA、F/T、T分期、Gleason评分差异无显著性(P>0.05)。VV和VL+LL各评价预后指标差异无显著性(P>0.05)。分段评价PSA水平、Gleason评分、临床分期、年龄,均与两种基因型无相关性(P>0.05)。结论:V89L多态性与预后无明显关系,但是可能与前列腺癌的风险存在间接的关系。
Objective: To investigate the relationship between the V89L polymorphism of testosterone 5-α reductase Ⅱ (SRD5A2) gene and the prognosis of prostate cancer. Methods: The V89L polymorphism sites were identified by Rsa-1 restriction endonuclease digestion. The differences in the distribution of V89L (VV, VL, LL) polymorphisms in 112 cases of prostate cancer and 89 cases of BPH were observed And its polymorphism with the age of patients with prostate cancer, PSA, free PSA / total PSA (tPSA / fPSA, F / T), Gleason score, clinical stage. RESULTS: There was no significant difference in the frequency of V89L gene among 112 prostate cancer patients and 89 BPH patients (χ2 = 3.606, df = 2, P = 0.165). The genotypes of VV and VL + LL in prostate cancer group were not significantly different from those of fPSA, tPSA, F / T, T stage and Gleason score (P> 0.05). VV and VL + LL evaluation of prognostic indicators no significant difference (P> 0.05). Segmental evaluation of PSA level, Gleason score, clinical stage, age, no correlation with the two genotypes (P> 0.05). Conclusion: The V89L polymorphism has no obvious relationship with prognosis, but it may have an indirect relationship with the risk of prostate cancer.